HGF/c-Met在鼻内翻性乳头状瘤中的表达及与其恶变的关系  

Expressions of HGF/c-Met in nasal inverted papilloma and their relationship with malignant transformation

作　　者：段晓辉[1] 于艳芳[1] 裴志萍[2] 张艳丽[1] 王延臣[1] 乔国勇[1] 康震[1] 

机构地区：[1]河北工程大学附属医院耳鼻咽喉科,邯郸056002 [2]邯郸市第二医院普外科,邯郸056001

出　　处：《重庆医科大学学报》2013年第8期885-888,共4页Journal of Chongqing Medical University

摘　　要：目的:检测肝细胞生长因子(hepatocyte growth factor,HGF)/c-Met系统在鼻内翻性乳头状瘤中的表达及探索与其恶变的关系。方法:选择我院2005-2010年间确诊为鼻内翻性乳头状瘤(实验组1)患者30例及鼻腔恶性乳头状瘤(实验组2)患者12例作为实验组,选取鼻息肉(对照组1)患者28例、慢性肥厚性鼻炎(对照组2)患者18例作为对照组,对实验组织采用免疫组织化学方法 SP法检测HGF/c-Met的表达,并统计其染色得分。Real-time PCR检测手术切除组织HGF与c-Met基因表达。结果:实验组统计得分明显高于对照组,且实验组内鼻腔恶性乳头状瘤的统计得分均值要高于内翻性乳头状瘤(P<α’)。Real-time PCR也得到和免疫组织化学染色一致的结果。结论:HGF/c-Met的高表达可能和内翻性乳头状瘤的恶变有关。检测HGF/c-Met的表达可对内翻性乳头状瘤是否有恶变风险和判断预后提供依据。Objective： To detect the expressions of hepatocyte growth factor（HGF）/c-Met system in nasal inverted papilloma and to explore the relationship between HGF/c-Met expressions and malignant transformation. Methods：Totally 30 cases of defined nasal in- verted papilloma and 12 cases of nasal malignant papilloma were chosen as experimental group while 28 cases of nasal polyps and 18 cases of chronic hypertrophic rhinitis were defined as control group. All samples were selected in our hospital from 2005 to 2010. Sur- gical treatment was applied to dissect the disease tissues,immunohistochemical SP was used to detect the expressions of HGF/c-Met and staining scores of the samples were calculated. HGF and c-Met mRNA level of removed tissues were detected by real-time PCR. Results：Statical score of experimental group was significantly higher than that of control group. In experimental group, score of malig- nant palilloma was higher than that of inverte papilloma. Real-time PCR results were similar to those of immunohistochemistry. Conclusions ： High expressions of HGF/c-Met may relate with malignant transformation of inverted papilloma. Detecting HGF/c-Met expression may provide references for judging the malignant risk and prognosis of inverted papilloma.

关 键 词：肝细胞生长因子 C-MET 内翻性乳头状瘤 恶变 

分 类 号：R739.62[医药卫生—肿瘤]